Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Pulmonx (Nasdaq:LUNG) granted equity awards under its 2025 Inducement Plan to 17 new employees hired in the first two quarters of 2026. According to Pulmonx, these Nasdaq Listing Rule 5635(c)(4) inducement awards total 84,300 RSUs with four-year vesting starting on June 1, 2026.
Positive
- 84,300 RSUs granted to support hiring of 17 new employees
- Structured four-year vesting schedule may aid employee retention
Negative
- 84,300 new RSUs create incremental equity-based dilution for shareholders
News Market Reaction – LUNG
In the Jun 2 session, LUNG gained 1.26%, reflecting a mild positive market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Q1 2026 earnings | Neutral | +6.7% | Reported Q1 2026 results with lower revenue, strong margins, and reiterated guidance. |
| Apr 28 | Conference presentation | Neutral | -2.4% | Announced upcoming presentation at a major health care investor conference. |
| Apr 15 | Earnings call date | Neutral | -2.7% | Scheduled Q1 2026 earnings release and conference call details. |
| Mar 04 | FY 2025 earnings | Positive | +11.8% | Reported 2025 revenue growth to $90.5M, margin expansion, and 2026 guidance. |
| Mar 04 | New credit facility | Positive | +11.8% | Closed up to $60M credit facility to refinance debt and add liquidity. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent earnings-related news often saw positive price reactions, while conference and scheduling updates drew modest negatives, indicating stronger sensitivity to fundamentals than to routine announcements.
Over the last few months, Pulmonx has focused on financial performance, capital structure, and investor outreach. Q4 2025 and Q1 2026 results showed $90.5M 2025 revenue with improved gross margins but ongoing net losses, alongside a new credit facility of up to $60M. Earnings releases on Mar 4, 2026 and Apr 29, 2026 produced double‑digit and mid‑single‑digit gains, while conference and earnings‑date notices saw small declines. Today’s inducement RSUs fit into ongoing use of equity compensation alongside prior insider RSU grants.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock units financial
rsus financial
inducement plan financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on June 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to 17 individuals hired by Pulmonx in the first two quarters of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing Rule 5635(c)(4). Each award is subject to the terms and conditions of the Inducement Plan and the grant agreements covering the awards.
The employees received in the aggregate 84,300 restricted stock units (“RSUs”). In each case, one-fourth of the RSUs will vest on the one-year anniversary of the Grant Date, with the remainder vesting in equal quarterly installments over the subsequent three-year period, subject to such employee’s continuous employment on each vesting date.
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees or directors of Pulmonx, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Pulmonx, pursuant to Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was adopted by the Company’s Board of Directors in November 2025.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation
Investor Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
